Anavex Seeks EU Approval, But The Data Says Otherwise

2025-01-14 17:39:38 ET

Summary

• Anavex's blarcamesine faces efficacy, trial design, and safety concerns, with high dropout rates and no functional improvements over placebo in Alzheimer's trials.
• Despite a 20% stock rally from EU market application acceptance, regulatory approval is uncertain due to data quality and safety issues.
• Anavex's financial health is stable with cash runway into 2028, but rising expenses are expected as they pursue late-stage development and potential launch.
• I maintain a "strong sell" rating on AVXL, anticipating a significant stock drop after likely EMA rejection of blarcamesine later this year.

Noisy Data and Dropouts Cloud Anavex’s Alzheimer’s Drug

Anavex Life Sciences ( AVXL ) is developing blarcamesine, a sigma-1 receptor agonist, for the treatment of early Alzheimer’s disease (AD). Since my " strong sell " recommendation (with a four-year evaluation period) in October, its stock has rallied over 90%. My issues with Anavex stem from its decision to pursue an Alzheimer’s indication in the EU without robust clinical data....

Read the full article on Seeking Alpha

For further details see: